A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open label, randomized, crossover trial. Current Medical Research & Opinion, pp.2805-2815, 2009. ,
Efficacy of intranasal fentanyl spray versus other opioïds for breakthrough pain in cancer, Current Medical Research & Opinion, vol.26, pp.1037-1045, 2010. ,
Options et Recommandations 2002 pour les traitements antalgiques médicamenteux des douleurs cancéreuses par excès de nociception chez l'adulte, mise à jour ,
Recommandations pour une bonne pratique dans la prise en charge de la douleur du cancer chez l'adulte et l'enfant, Bull Cancer, vol.83, issue.1, pp.9-79, 1996. ,
Morphine and alternative opioïds in cancer pain: the EAPC recommendations, British Journal of Cancer, vol.84, pp.587-593, 2001. ,
Utilisation de l'entredose de morphine ,
Médecine générale, pp.17-19, 1997. ,
Evidence based guidelines for the use of opioid analgesics in the treatment of cancer pain: The 2011 EAPC recommendations ,
Caractéristiques et prise en charge médical des accès douloureux transitoires, pp.226-231, 2001. ,
éducation pour la santé (INPES) et Mission interministérielle de lutte contre la drogue et la toxicomanie (MILDT) 17-National institute on drug abuse. Fentanyl Oral transmucosal abuse of transdermal fentanyl, J Psychopharmacol, vol.18, pp.277-80, 2004. ,
The fentanyl tea bag, Vet Hum Toxicol, vol.46, pp.30-31, 2004. ,
A delirious patient with opioid intoxication after chewing a fentanyl patch, J Am Geriatr Soc, vol.54, pp.1298-1307, 2006. ,
Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study, Am J of hospice and palliative care, vol.25, pp.447-451 ,
A phase II study to establish the efficacy and toxicity of Sodium Valproate in patients with cancer related neuropathic pain, Journal of pain and symptom management, vol.21, pp.204-209, 2001. ,
A role for intravenous Lidocaïne in severe cancerrelated neuropathic pain at the end of life. Supportive care cancer, pp.899-901, 2010. ,
Flecaïnide in cancer nerve pain. The Lancet, p.1347, 1991. ,
Effect of Melixetine on vincristine induced painful neuropathy in mice, European Journal of Pharmacology, vol.536, pp.123-130, 2006. ,
Options et Recommandations pour l'évaluation de la douleur chez l'adulte et l'enfant atteints d'un cancer ,
Histoire, définition et caractéristiques des ADP. Douleurs Evaluation Diagnostic et Traitement, pp.1-4, 2010. ,
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey, Palliative Medicine, vol.18, pp.177-183, 2004. ,
Temporal Presentation of Chronic Cancer Pain: Transitory Pains on Admission to a Multidisciplinary Pain Clinic, Journal of pain symptom management, vol.17, pp.391-401, 1999. ,
Prevalence and characteristics of breakthrough pain in cancer patients admitted to a Hospice, Journal of pain symptom management, vol.20, pp.87-92, 2000. ,
Breakthrough pain: characteristics and impact in patients with cancer pain, Pain, vol.81, pp.129-134, 1999. ,
Characterization of Breakthrough Pain by Hospice Patients and Their Caregivers, Journal of Pain and Symptom Management, vol.16, pp.179-183, 1998. ,
Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain, Journal of Pain and Symptom Management, vol.24, pp.45-52, 2002. ,
The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland, European Journal of Pain, vol.13, pp.331-338, 2009. ,
The role of biphosphonates in the treatment of painful metastatic disease: a review of phase III trials, Pain, vol.78, pp.157-69, 1998. ,
Cancer-related breakthrough pain, pp.23-30, 2006. ,
Cancer-related breakthrough pain, pp.1-11, 2006. ,
Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain, pp.123-153, 2001. ,
The prevalence of episodic pain in cancer: a survey of hospice patients on admission, Palliative Medicine, vol.15, pp.9-18, 2001. ,
Absorption and Bioavailability of Oral Transmucosal Fentanyl Citrate, Anesthesiology, vol.75, pp.223-229, 1991. ,
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Current Médical Research Opinion, pp.2877-2885, 2009. ,
Fentanyl sublingual in breaktrough pain in opioïds tolerant patients, Drugs, vol.70, pp.2281-2288, 2010. ,
Fentanyl buccal tablet for relief of breakthrough pain in opioïd tolerant patients with cancer related chronic pain. The Journal of Supportive Oncology, pp.327-334, 2007. ,
A randomized placebo controlled study of fentanyl buccal tablet for breakthrough pain in opioïd treated patient with cancer, Clinical Journal of Pain, vol.22, pp.805-811, 2006. ,
Single dose and steady-state Pharmacokinetics of Fentanyl Buccal Tablet in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.47, pp.56-63, 2007. ,
Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain, Journal of opioïd management, vol.6, issue.1, pp.17-21, 2010. ,
Fentanyl-laced heroin: a report from an unexpected place, Am J Emerg Med, vol.27, issue.2, pp.237-246, 2009. ,
et al The Prevalence of Fentanyl in Drug-Related Deaths in Philadelphia, Journal of Medical Toxicology, vol.6, pp.9-11, 2004. ,
Development and validation of the pain treatment satisfaction scale (ptss): a patient satisfaction questionnaire for use in patients with chronic or acute pain, Pain, vol.112, pp.254-266, 2004. ,
Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Current Medical Research & Opinion, pp.1385-1394, 2011. ,